Collaboration for the evaluation of the antiviral potential of CDs

News 17 March, 2021
In May, 2020, CycloLab announced a collaboration, where University of California, Berkeley, Excivion and CycloLab teamed-up to evaluate the antiviral potential of cyclodextrins against SARS-CoV-2 and other viral infections. While the Covid-19 related results of this work are non public yet, we are happy to present non-confidential data on an also very important viral threat: Dengue virus.
In the past months we evaluated several cyclodextrin-based NCE candidates and hereby we present some of the very first promising results, while developing the program further.

Also, we are open to consider potential partners for taking the next steps together or sharing further insights. 

You can find the slidedeck here